Bachem stock gains as JPMorgan lifts price target to 90 CHF

Published on 09/10/2026 at 15:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bachem stock is trading near key analyst levels after JPMorgan raised its price target to 90 CHF on September 10, 2026. Barclays still holds a more cautious Hold stance with an 80 CHF target based on Q2 2026 results.

Fotorealistische Peptid-Produktionsanlage mit Alpenpanorama im Hintergrund — Bachem Holding AG (CH0012530207) betreibt moderne Peptid-Produktionsanlagen mit Bioreaktoren vor Schweizer Alpenpanorama, Illustration mit AI erstellt.

Bachem Holding AG stock (ISIN CH0012530207) is trading firmly supported by fresh analyst updates, after JPMorgan raised its price target to 90 CHF on September 10, 2026 while the shares remain close to earlier reference marks from Barclays.

Analyst moves set the tone

According to Goldesel on September 10, 2026, JPMorgan raised its price target for Bachem Holding AG from 85 CHF to 90 CHF and reiterated its Overweight rating, a 5.9 percent increase in the target that signals growing confidence in the company’s earnings trajectory.

The same overview from Goldesel notes that Bachem’s share price stood at 81.70 EUR on September 9, 2026 on the Lang & Schwarz Exchange, up 25.5 percent since the start of 2026, underscoring how the stock has steadily appreciated ahead of and around the latest analyst action.

Barclays sticks with Hold on Q2 figures

As Ad-hoc-news reported on September 9, 2026, Barclays analyst Charles Pitman maintained a Hold rating on Bachem Holding AG with a price target of 80.00 CHF, leaving both rating and target unchanged despite the share price trading in the 78 to 79 CHF range on SIX Swiss Exchange that day.

The same article from Ad-hoc-news highlights that Q2 2026 results were perceived as solid but not spectacular, with revenue increasing by around four percent year on year in the quarter and net profit remaining almost flat, a combination that helps explain why Barclays and much of the analyst consensus stay cautious at Hold instead of moving to more aggressive ratings.

An article from Ad-hoc-news also notes that Bachem stock at 78.40 CHF on September 9, 2026 was trading just about two percent below the 80.00 CHF target maintained by Barclays and the average of other analysts, and within the upper segment of a 52 week range between 50.00 CHF and 83.80 CHF, suggesting the current market valuation already prices in much of the recent operational progress.

Price level and valuation

Per data summarized from SIX Swiss Exchange via Ad-hoc-news, Bachem stock closed at 78.40 CHF on September 9, 2026 on SIX Swiss Exchange, placing the shares near the top of the stated 52 week range from 50.00 CHF to 83.80 CHF and only around two percent below the 80.00 CHF average analyst target.

At this level, the stock’s year to date performance of more than 30 percent against the MSCI World benchmark, as cited by Ad-hoc-news, illustrates the extent to which investors have rewarded the company for steady growth in its peptide and oligonucleotide business despite the cautious tone of some analyst houses.

Fundamentals behind the ratings

The Q2 2026 revenue increase of around four percent year on year and the almost flat net profit described by Ad-hoc-news for Bachem’s Q2 2026 results provide a numerical backdrop to the mixed analyst views, showing that while top line momentum is positive, profit growth has not yet accelerated to the same extent.

The Q2 2026 pattern described there means that revenue growth, at roughly four percent, outpaced net profit growth which was described as almost flat, creating a modest margin squeeze that analysts such as Barclays interpret as a reason to maintain a more cautious Hold stance even as they acknowledge the resilience of Bachem’s business.

Stock remains close to key reference levels

For investors watching Bachem stock as of September 10, 2026, the combination of JPMorgan’s higher 90 CHF target and Barclays’ unchanged 80 CHF target sets a relatively tight band of expectations, with the recent 78.40 CHF share price on September 9, 2026 sitting just below the lower end of that target range and within sight of the 83.80 CHF 52 week high.

This positioning, together with the more than 30 percent year to date gain versus the MSCI World index reported by Ad-hoc-news, shows Bachem in a zone where incremental earnings surprises or further analyst revisions could quickly influence the share price, given how close it already trades to key valuation markers.

Latest price snapshot

On SIX Swiss Exchange, Bachem stock most recently closed at 78.40 CHF on September 9, 2026, with the price sitting near the upper end of the stated 52 week range between 50.00 CHF and 83.80 CHF and only around two percent below the 80.00 CHF consensus target, reflecting a market that broadly prices in the company’s current Q2 2026 revenue growth and cautious profit profile.